![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
AstraZeneca plans next phase of trial on kidney drug combination data
(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.
Read more